37 results on '"Dolzhikova, Inna V."'
Search Results
2. New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses
3. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
4. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
5. Cytokine production in an ex vivo model of SARS-CoV-2 lung infection.
6. Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2 Lineages Including Far-Distanced Omicron BA.5.
7. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
8. Lethality of West Nile virus strains in a mouse model
9. Vaccines to prevent Ebola virus disease: current challenges and perspectives
10. Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
11. In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
12. Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study
13. rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
14. Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus
15. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
16. SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case
17. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals
18. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study
19. COVID-19 vaccination and HIV-1 acquisition
20. Boosting of the SARS-CoV-2–Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine
21. Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
22. Fast and Accurate Surrogate Virus Neutralization Test Based on Antibody-Mediated Blocking of the Interaction of ACE2 and SARS-CoV-2 Spike Protein RBD
23. Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern, including Omicron variant
24. Boosting of the SARS-CoV-2-specific immune response after vaccination with single-dose Sputnik Light vaccine
25. One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow
26. SARS-CoV-2 specific T cells and antibodies in COVID-19 protection: a prospective study
27. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants
28. Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial – Authors' reply
29. Impact of pathogen reduction methods on immunological properties of the COVID‐19 convalescent plasma
30. Development and Characterization of Hyperimmune Anti-SARS-CoV-2 Intravenous Immunoglobulin From COVID-19 Convalescent Plasma
31. An Open, Non-Randomised, 1/2 Phase Study on the Safety, Tolerability, and Immunogenicity of Single Dose 'Sputnik Light' Vaccine for Prevention of Coronavirus Infection in Healthy Adults
32. Integrated into Environmental Biofilm Chromobacterium vaccinii Survives Winter with Support of Bacterial Community
33. Preclinical studies of immunogenity, protectivity, and safety of the combined vector vaccine for prevention of the middle east respiratory syndrome
34. Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma
35. Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors’ reply
36. Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses
37. Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.